Abstract
An NCI workshop entitled “Frontiers in Metabolomics for Cancer Research” was held in October 2005 to identify gaps in the application of metabolomics for cancer research and to disseminate information on metabolomics and its potential application. The workshop was sponsored by a number of groups, including the Division of Cancer Prevention, the Division of Cancer Biology, the Division of Cancer Epidemiology and Genetics, and the Center for Cancer Research within the National Cancer Institute, as well as the National Institutes of Health (NIH) Office of Dietary Supplements. Specific aims for the workshop were to (1) identify issues relevant to the use of metabolomics in the measurements of changes in cells or body fluids; (2) review a variety of approaches to metabolite-based phenotyping such as metabolomics arrays and spectroscopic profiles in relation to its application for patients and/or stratification for responders and non-responders to dietary components, drugs, and toxic agents; (3) discuss what additional information metabolomics provides over that given by genomics and/or proteomics; and (4) evaluate the current status of metabolomics technologies as they relate to cancer prevention research. The potential impact of emerging metabolomics technology and research approaches on our understanding of interactions among external environments is obvious. The study of metabolomics, as characterized by the study of small molecular weight compounds, has the promise of discerning subtle changes in metabolic pathways and shifts in mechanistic aspects of homeostasis—within a time span of seconds—that is not possible by other “omic” approaches. Another advantage is that metabolomic research findings are likely to be relevant to a wide range of chronic and/or infectious diseases, including cancer obesity, and cardiovascular disease. This manuscript is a summary of the workshop that highlighted the existing research and literature in the field of metabolomics for cancer research and research recommendations that may provide important steps forward for the future.
Similar content being viewed by others
References
Almaas, E., Kovacs, B., Vicsek, T., et al. (2004). Global organization of metabolic fluxes in the bacterium Escherichia coli. Nature, 427, 839–843.
Arias-Mendoza, F., Smith, M. R., & Brown, T. R. (2004). Predicting treatment response in non-Hodgkin’s lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Academic Radiology, 11, 368–376.
Boren, J., Cascante, M., Marin, S., et al. (2001). Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. The Journal of Biological Chemistry, 276, 37747–37753.
Brindle, J. T., Antti, H., Holmes, E., et al. (2002). Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nature Medicine, 8, 1439–1445.
Brown, S. C., Kruppa, G., & Dasseux, J. L. (2005). Metabolomics applications of FT-ICR mass spectrometry. Mass Spectrometry Reviews, 24, 223–231.
Cheng, L. L., Burns, M. A., Taylor, J. L., et al. (2005). Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Research, 65, 3030–3034.
Cramer, C. T., Goetz, B., Hopson, K. L., et al. (2004). Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. Journal of Lipid Research, 45, 1289–1301.
Duarte, N. C., Palsson, B. O., & Fu, P. (2004). Integrated analysis of metabolic phenotypes in Saccharomyces cerevisiae. BMC Genomics, 5, 63.
Ellis, D. I., Dunn, W. B., Griffin, J. L., et al. (2007). Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics, 8, 1243–1266.
Fiehn, O., Kristal, B., van Ommen, B., et al. (2006). Establishing reporting standards for metabolomic and metabonomic studies: A call for participation. Omics: A Journal of Integrative Biology, 10, 158–163.
Griffin, J. L., & Kauppinen, R. A. (2007). A metabolomics perspective of human brain tumours. The FEBS Journal, 274, 1132–1139.
Griffin, J. L., & Nicholls, A. W. (2006). Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders. Pharmacogenomics, 7, 1095–1107.
Griffin, J. L., & Shockcor, J. P. (2004). Metabolic profiles of cancer cells. Nature Reviews. Cancer, 4, 551–561.
Griffiths, J. R., & Stubbs, M. (2003). Opportunities for studying cancer by metabolomics: Preliminary observations on tumors deficient in hypoxia-inducible factor 1. Advances in Enzyme Regulation, 43, 67–76.
Hakumaki, J. M., Poptani, H., Sandmair, A. M., Yla-Herttuala, S., & Kauppinen, R. A. (1999). 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: Implications for the in vivo detection of apoptosis. Nature Medicine, 5, 1323–1327.
Hardt, P. D., Mazurek, S., Toepler, M., et al. (2004). Faecal tumour M2 pyruvate kinase: A new, sensitive screening tool for colorectal cancer. British Journal of Cancer, 91, 980–984.
Harkewicz, R., Fahy, E., Andreyev, A., & Dennis, E. A. (2007). Arachidonate-derived dihomoprostaglandin production observed in endotoxin-stimulated macrophage-like cells. The Journal of Biological Chemistry, 282, 2899–2910.
Ibarra, R. U., Fu, P., Palsson, B. O., DiTonno, J. R., & Edwards, J. S. (2003). Quantitative analysis of Escherichia coli metabolic phenotypes within the context of phenotypic phase planes. Journal of Molecular Microbiology and Biotechnology, 6, 101–108.
Kaddurah-Daouk, R. (2006). Metabolic profiling of patients with schizophrenia. PLoS Medicine, 3, e363.
Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., et al. (2007). Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Molecular Psychiatry, 12, 934–945.
Kell, D. B., & King, R. D. (2000). On the optimization of classes for the assignment of unidentified reading frames in functional genomics programmes: The need for machine learning. Trends in Biotechnology, 18, 93–98.
Lamers, R. J., DeGroot, J., Spies-Faber, E. J., et al. (2003). Identification of disease- and nutrient-related metabolic fingerprints in osteoarthritic Guinea pigs. The Journal of Nutrition, 133, 1776–1780.
Lee, W. N., & Go, V. L. (2005). Nutrient–gene interaction: Tracer-based metabolomics. The Journal of Nutrition, 135(Suppl. 12), 3027S–3032S.
Mazurek, S., Grimm, H., Boschek, C. B., Vaupel, P., & Eigenbrodt, E. (2002). Pyruvate kinase type M2: A crossroad in the tumor metabolome. The British Journal of Nutrition, 87(Suppl. 1), S23–S29.
Mendes, P. (2006). Metabolomics and the challenges ahead. Briefings in Bioinformatics, 7, 127.
Mendes, P., Camacho, D., & de la Fuente, A. (2005). Modelling and simulation for metabolomics data analysis. Biochemical Society Transactions, 33, 1427–1429.
Muoio, D. M., & Newgard, C. B. (2006). Obesity-related derangements in metabolic regulation. Annual Review of Biochemistry, 75, 367–401.
Nicholson, J. K., & Wilson, I. D. (2003). Opinion: Understanding ‘global’ systems biology: Metabonomics and the continuum of metabolism. Nature Reviews. Drug Discovery, 2, 668–676.
Oliver, S. G. (2002). Functional genomics: Lessons from yeast. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 357, 17–23.
Poitout, V., & Robertson, R. P. (2002). Minireview: Secondary beta-cell failure in type 2 diabetes—A convergence of glucotoxicity and lipotoxicity. Endocrinology, 143, 339–342.
Rozen, S., Cudkowicz, M. E., Bogdanov, M., et al. (2005). Metabolomic analysis and signatures in motor neuron disease. Metabolomics, 1, 101–108.
Salek, R. M., Maguire, M. L., Bentley, E., et al. (2007). A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and man. Physiological Genomics, 29, 99–108.
Sauer, U. (2006). Metabolic networks in motion: 13C-based flux analysis. Molecular Systems Biology, 2, 1–10.
Schipper, R. G., Romijn, J. C., Cuijpers, V. M. J. I., et al. (2003). Polyamines and prostatic cancer. Biochemical Society Transactions, 31, 375–380.
Serkova, N. J., Spratlin, J. L., & Eckhardt, S. G. (2007). NMR-based metabolomics: Translational application and treatment of cancer. Current Opinion in Molecular Therapeutics, 9, 572–585.
Solanky, K. S., Bailey, N. J., Beckwith-Hall, B. M., et al. (2003). Application of biofluid 1H nuclear magnetic resonance-based metabonomic techniques for the analysis of the biochemical effects of dietary isoflavones on human plasma profile. Analytical Biochemistry, 323, 197–204.
Tonus, C., Neupert, G., & Sellinger, M. (2006). Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World Journal of Gastroenterology, 12, 7007–7011.
Acknowledgments
The authors would like to thank Darrell Anderson and Stefanie Nelson of the Scientific Consulting Group, Inc., Gaithersburg, MD, for their assistance in preparing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, Y.S., Maruvada, P. Frontiers in metabolomics for cancer research: Proceedings of a National Cancer Institute workshop. Metabolomics 4, 105–113 (2008). https://doi.org/10.1007/s11306-008-0109-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11306-008-0109-3